We are a clinical-stage biopharmaceutical company focused on novel cancer immunotherapy products. We utilize the body’s own machinery – the T cell – to target and destroy cancer cells by increasing the affinity of naturally occurring T cell receptors (TCRs). Our lead program, utilizing our NY-ESO TCR therapeutic, has generally been well tolerated in Phase 1/2 trials in solid tumors and in hematologic cancer types and we have seen responses and preliminary evidence of tumor reduction in patients with highly refractory cancers. An IND is now open for our MAGE-A10 TCR therapy. The initial clinical program will be in patients with advanced stage NSCLC. We continue to build a pipeline of TCR therapeutic candidates targeting a number of additional cancer targets. We have a research base in Oxford, UK and a clinical base in Philadelphia, US.